Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148486
Status:
COMPLETED
Last Update Posted:
2013-10-29
First Post:
2005-09-07
Brief Title:
A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinsons Disease Patients Study for Proof of Concept in Early Parkinsons Disease of a Triple Reuptake Inhibitor NS 2330 SCEPTRE
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Fourteen-week Placebo-controlled Dose-response Efficacy and Safety Study of NS 2330 in Early Parkinsons Disease Patients Study for Proof of Concept in Early Parkinsons Disease of a Triple Reuptake Inhibitor NS 2330 SCEPTRE
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinsons Disease in 14 weeks of treatment and to investigate the safety and tolerability of NS 2330 in these patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None